Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health through anti-inflammatory, vascular, and neuroprotective mechanisms.

We’re uncovering how metabolism connects to addiction, behaviour, and chronic disease in ways we never imagined...” ...

Nugevia™ supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss Jupiter ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Food brands are racing to respond to GLP‑1 drugs, but major misconceptions persist. From R&D realities to ex‑GLP‑1 users, here are the key insights shaping the market.

About 20 years ago, the U.S. Food and Drug Administration approved the first GLP-1 medication for Type 2 diabetes. Today, the landscape has shifted, as the agency has approved various ...

One of the assets shelved by Eli Lilly is a gene therapy for dementia, which it obtained in its $1.04-billion acquisition of ...

GI side effects. These are common with these medications and can include nausea, diarrhea, abdominal pain, and vomiting. “Symptoms are often tolerable in younger patients; they can precipitate serious ...

Thousands of patients are suing over alleged GLP-1 drug injuries. Drugs include Ozempic, Wegovy and Mounjaro.

Drugs like Ozempic and Wegovy are at the forefront of a health revolution. Originally used to treat diabetes, then obesity, these GLP-1 receptor agonists – drugs that mimic a hormone that reduces ...

Patients with a heart failure history and preserved ejection fraction appeared to benefit ...